The Pharma Data

JANUARY 27, 2021

MultiStem ® cell therapy is a patented regenerative medicine product candidate in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. 28, 2021 11:00 UTC. About MultiStem ®.

Clinical Trials 52

Clinical Trials Clinical Trials Production Trials 52

The Pharma Data

DECEMBER 23, 2020

The lead Principal Investigator for the INNOVATE trial is Dr. Pablo Tebas , Professor of Medicine at the Hospital of the University of Pennsylvania. About INOVIO’s DNA Medicines Platform. INOVIO’s DNA medicines do not interfere with or change in any way an individual’s own DNA.

DNA 40

DNA Vaccine Vaccination Immune Response 40

The Pharma Data

JULY 21, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

Vaccine 52

Vaccine Vaccination Manufacturing Clinical Trials 52

The Pharma Data

NOVEMBER 15, 2020

NASDAQ: ATHX), a clinical-stage regenerative medicine company, is pleased to announce that it has appointed Ms. 16, 2020 11:00 UTC. CLEVELAND–( BUSINESS WIRE )– Athersys, Inc. Katherine Kalin, Ms. Jane Wasman and Mr. Baiju R. Shah to its board of directors. About MultiStem ®. More information is available at www.athersys.com.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

XTalks

JANUARY 29, 2021

Biosimilars are increasingly becoming the standard of care and both have several licensed biosimilar drugs (e.g. Clinical Services International is a trusted partner of leading pharmaceutical and biotechnology companies, contract research organisations, and contract manufacturing organisations.

Clinical Trials 104

Clinical Trials Clinical Trials Production Trials 104

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Antibody 52

Antibody Licensing Licensing Development 52

pharmaphorum

NOVEMBER 5, 2021

The company said it plans to adopt a tiered pricing approach to the drug depending on a country’s income, and is “exploring” contract manufacturing deals to for less well-off nations.

DNA 116

DNA Contract Manufacturing HR Manufacturing 116

The Pharma Data

NOVEMBER 5, 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Dupixent, recommending to extend the approval in the EU to include children aged 6 to 11 years with severe atopic dermatitis who are candidates for systemic therapy. Oncology Program. 50% PD-L1 expression.

Sales 40

Sales Production Manufacturing Antibody 40

pharmaphorum

JUNE 2, 2021

Capacity to supply Moderna’s COVID-19 vaccine in Europe could be swelled by round 300 million doses a year, following an agreement to set up a new production line at contract manufacturer Lonza. Full approval means it could be used routinely in future as an annual booster, much like the seasonal influenza vaccine.

Vaccine 52

Vaccine Vaccination Contract Manufacturing Production 52

The Pharma Data

JUNE 24, 2021

The production capacity has consistently grown due to continued enhancements to the vaccine’s supply chain, which include expanding existing facilities, adding more suppliers, and bringing on additional Pfizer/BioNTech sites and contract manufacturers around the world to produce the vaccine.

Vaccine 52

Vaccine Vaccination Manufacturing Clinical Trials 52

The Pharma Data

NOVEMBER 19, 2021

Pfizer has also begun and will continue to invest up to roughly$ 1 billion of its own finances to support the manufacturing and distribution of this investigational treatment seeker, including exploring implicit contract manufacturing options.

HR 52

HR Contract Manufacturing Manufacturing Clinical Trials 52

The Pharma Data

MARCH 22, 2022

Pfizer continues to invest to support the manufacturing and distribution of PAXLOVID, including exploring potential contract manufacturing options. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

In-Vitro 52

In-Vitro Contract Manufacturing Manufacturing Development 52

The Pharma Data

NOVEMBER 17, 2021

Pfizer has begun and will continue to invest up to roughly$ 1 billion of its own finances to support the manufacturing and distribution of this investigational treatment seeker. It has entered into advance purchase agreements with several countries and has initiated bilateral outreach to roughly 100 countries around the world.

HR 52

HR Manufacturing Contract Manufacturing Licensing 52

The Pharma Data

MAY 4, 2021

Internal Medicine. billion, primarily driven by Pfizer CentreOne, Pfizer’s contract manufacturing operation, reflecting sales of legacy Upjohn products to Viatris (4) and remdesivir to Gilead Sciences Inc., REVENUES. . . . . . ($ in millions). First-Quarter. . 1,611. . *. *. Inflammation & Immunology. Rare Disease.

Vaccine 40

Vaccine Vaccination Production Sales 40